Dernières nouvelles pour ARK Genomic Revolution ETF (BATS:ARKG)

ARK Genomic Revolution Multi-Sector ETF

Healthcare

Consumer Cyclical

The Fund is an actively managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80 percent of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the Funds investment theme of the genomics revolution (Genomics Revolution Companies). Under normal circumstances, substantially all of the Funds assets will be invested in equity securities, including common stocks, partnership interests, business trust shares and other equity investments or ownership interests in business enterprises. The Funds investments will include micro-, small-, medium- and large-capitalization companies. The Funds investments in foreign equity securities will be in both developed and emerging markets.

Twist Bioscience Corp.

Caredx

Crispr Therapeutics Ag

Recursion Pharmaceuticals, Inc.

Ionis Pharmaceuticals Inc

Intellia Therapeutics

Beam Therapeutics Inc

Schrodinger, Inc.

Adaptive Biotechnologies Corporation

10X Genomics Inc

Tempus Pe

Natera Inc

Guardant Health Inc.

ARK Genomic Revolution ETF

ChampionX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHX#NASDAQ">CHX</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.43 by 16.28 percent. This is unchanged from the same period last year. The company reported quarterly sales of $864.46 million which missed the analyst consensus estimate of $895.94 million by 3.51 percent. This is a 6.25 percent decrease over sales of $922.14 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

ChampionX Q1 Adj. EPS $0.50 Beats $0.43 Estimate, Sales $864.46M Miss $895.94M Estimate

Nuo Therapeutics, Inc. (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/AURX#OTCQB">AURX</a>) ("Nuo"), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced it has entered into an exclusive private label distribution agreement ("Agreement") with global medical technology company Smith+Nephew ((LSE:SN, NYSE:<a href="https://www.benzinga.com/stock/SNN#NYSE">SNN</a>). Under the Agreement, Smith+Nephew will market and sell CENTRIO Platelet-Rich Plasma System, their own branded version of Nuo's underlying Aurix&#xAE; System to the United States wound care market. Nuo will continue to be responsible for manufacturing the product.&nbsp;&nbsp; The Aurix product brand sold separately by Nuo will remain in the market under Nuo's full control and will be fully available commercially subject to certain customer overlap conditions more fully addressed in the Agreement.&nbsp;&nbsp;
"This exclusive private label distribution agreement with Smith+Nephew is a significant development for Nuo," commented David Jorden, Nuo's Chief Executive and Financial Officer. "We could not envision a better participant in the advanced wound care market to work with collaboratively to develop the platelet-rich plasma (PRP) market, as we believe the most important beneficiary will be patients suffering the many consequences of non-healing chronic wounds. We firmly believe Smith+Nephew's market leading position and significant market access and development resources offer the opportunity for broader awareness and adoption of autologous PRP. We are truly honored that Smith+Nephew's review of the available PRP products resulted in their decision to seek distribution rights to the underlying Aurix technology."
"Smith+Nephew looks forward to providing CENTRIO PRP technology later this year to our customers, and the patients they care for, as we look to expand treatment options and advance the continuum of wound care," said Vincent Fath, Senior Vice President and General Manager, US Advanced Wound Management. "We are pleased to be working in collaboration with Nuo as our supply partner for this exciting opportunity."
"The path Nuo has followed since the establishment of mandated coverage for PRP in the management of chronic wounds with the 2021 National Coverage Decision has successfully brought us this point," concluded Jorden. "We have much still to accomplish and while the market environment for advanced wound care therapies will continue to evolve, the dedicated Nuo team is eager for the opportunity. We look forward to sharing future developments and progress as we work to position Nuo for long term success."
In exchange for Smith+Nephew's exclusive distribution rights for CENTRIO over the initial term of five years, Nuo has received an upfront distribution fee, and will be entitled to certain minimum purchase commitments at agreed transfer pricing. Nuo will also be eligible to receive certain reimbursement coverage milestone payments subject to successful achievement of additional reimbursement coverage conditions. Additional information concerning the distribution agreement can be found in Nuo's Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 1, 2025.

Contracts

AURX

Nuo Therapeutics Enters Into Exclusive Private Label Distribution Agreement With Global Medical Technology Company For The CENTRIO Platelet-Rich Plasma System

General

KBR Chosen As Strategic Commercialization Partner for Samsara Eco's Groundbreaking Enzymatic Recycling Facility.

Veralto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLTO#NYSE">VLTO</a>) is looking for Q2 Adj EPS of $0.84-$0.88 vs $0.91 analyst estimate..

Guidance

VLTO

Veralto Sees Q2 Adj EPS $0.84-$0.88 vs $0.91 Est

Franklin Street Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/FSP#AMEX">FSP</a>) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $0.02 by 50 percent. This is a 25 percent decrease over earnings of $0.04 per share from the same period last year. The company reported $27.11 million in sales this quarter. This is a 13.19 percent decrease over sales of $31.23 million the same period last year.

Franklin Street Props Q1 FFO $0.03 Beats $0.02 Estimate, Sales $27.11M Down From $31.23M YoY

Veralto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLTO#NYSE">VLTO</a>) affirms FY2025 Adj EPS guidance from $3.60-$3.70 to $3.60-$3.70 vs $3.66 analyst estimate..

Veralto Affirms FY2025 Adj EPS Guidance of $3.60-$3.70 vs $3.66 Est

WIIM

ETWO

E2open Parent Holdings shares are trading higher. The company reported Q4 financial results.

Tech company and Snapchat parent Snap Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) reported first-quarter financial results after<a href="https://www.benzinga.com/earnings"> market close Tuesday.</a>
Here are the key highlights.
What Happened: Snap reported first-quarter revenue of $1.36 billion, up 14% year-over-year. The revenue total beat a Street consensus estimate of $1.35 billion according to data<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0429"> from Benzinga Pro.</a>
The company reported an adjusted loss of 8 cents per share, beating a Street consensus estimate of a loss of 13 cents per share.
Snap had 460 million daily active users at the end of the first quarter, up 9% year-over-year. The company also passed the milestone figure of 900 million monthly active users, on its way to a goal of one billion MAU. &nbsp;
The company's adjusted EBITDA was $108 million in the quarter, an improvement of 137% year-over-year.
"We surpassed an important milestone in Q1, with our community growing to over 900 million monthly active users," Snap CEO Evan Spiegel said.
Spiegel said progress was made in advertising solutions and Snapchat+ subscriptions in the quarter.
Active advertisers in the quarter were up 60% year-over-year.
Read Also: <a href="https://www.benzinga.com/25/04/44832468/snapchat-rejection-resurfaces-as-mark-zuckerberg-defends-meta-in-ftc-trial-and-the-tech-mogul-still-thinks-he-couldve-done-it-better-we-would-have-accelerated-their-growth">Mark Zuckerberg Defends Meta In FTC Trial Over $6 Billion Offer To Acquire Snapchat: &#8216;We Would Have Accelerated Their Growth&#8217;</a>
 What's Next: Snap is not providing formal guidance for the second quarter.
"Given the uncertainty with respect to how macro economic conditions may evolve in the months ahead, and how this may impact advertising demand more broadly, we do not intend to share formal financial guidance for Q2," the company said.
Snap said its revenue has continued to grow, but there are headwinds at the start of the second quarter.
The company is guiding for daily active users to be 468 million in the second quarter.
"While there is uncertainty regarding the macro operating environment, we remain optimistic about the long term prospects for our business."
The company said it is optimistic about the progress it made with its ad platform, the growth of Snapchat+, and because of its strong balance sheet.
"We will remain focused on executing against our strategic priorities of growing our community and improving depth of engagement, driving top line revenue growth and diversifying our revenue sources, and building toward our long term vision for augmented reality (AR)."
SNAP Price Action: Snap stock is down 12% to $8.00 in after-hours trading versus a 52-week trading range of $7.08 to $17.33. Snap shares were up 2.9% to $9.09 in the intraday trading session.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/03/44527218/snap-ceo-says-a-perfect-snapchat-employee-has-these-3-qualities">Snap CEO Says A &#8216;Perfect&#8217; Snapchat Employee Has These 3 Qualities</a></li>
</ul>
Photo: Shutterstock

Social Media

Movers

Tech

Trading Ideas

SNAP

Snap Hits 900 Million Users, Beats Q1 Estimates, But Stock Slides On 'Uncertainty'

BRSP

BrightSpire Capital Q1 Adj. EPS $0.16, Inline, Sales $15.85M Miss $17.60M Estimate

Legal

AREN

The Arena Group Settles Litigation With Authentic Brands Group; Terms Not Disclosed

Wall Street betting markets are on fire just hours before the first-quarter GDP release, with odds of a negative U.S. growth print soaring after months of trade war escalation and a <a href="https://www.benzinga.com/25/04/45072497/us-trade-deficit-explodes-to-record-162-billion-in-march-as-import-frenzy-precedes-trumps-tariff-barrage">record-breaking goods deficit.</a>
According to Kalshi, a CFTC-regulated prediction market, the probability of a contraction in U.S. GDP for the first quarter surged to 65% on Tuesday, just one day before the data drop. The implied reading now point to negative 0.4%, the lowest since late February 2025. 
Odds for a positive GDP reading tumbled by 30 percentage points to 39%, implying a $100 bet would return $245 if U.S. economy averts a quarterly contraction.
The economist consensus, as tracked by Trading Economics, still projects a 0.4% annualized expansion, down sharply from the 2.8% pace recorded in the fourth quarter of 2024.
The U.S. economy has not recorded a negative quarterly growth since the first quarter of 2022.
<iframe loading="lazy" src="https://kalshi.com/external-widgets/events/KXGDP-25APR30?color_scheme=light&#038;widget_size=large&#038;utm_campaign=benzinga_widget" width="552px" height="400px" style="border:0"></iframe>
<h3 class="wp-block-heading">Trade Deficit Smashes Records, Weighing On GDP</h3>
A major factor dragging down the GDP outlook has been the surge in America&#8217;s trade deficit, as U.S. manufacturers rushed to stockpile imports in anticipation of higher costs stemming from Donald Trump&#8216;s new tariffs.
The U.S. goods trade deficit widened to a historic $161.9 billion in March 2025, obliterating Wall Street's $145 billion estimate and marking a sharp deterioration from February's already massive $147.8 billion gap. 
January and February also recorded the second—and third-highest monthly deficits ever recorded, underscoring the persistent strain on America's trade flows.
Ballooning trade deficits directly drag GDP calculations, as net exports subtract from overall output. The bigger the deficit, the larger the negative contribution to economic growth.
<h3 class="wp-block-heading">Liberation Day Tariffs Stoke Fears of 2020-Style Shock, Analyst Says</h3>
In a note shared last week, Oskar Vårdal, macro analyst at Steno Research, said the current economic dynamics resemble those seen during the early days of the COVID-19 lockdowns in March 2020, when global supply chains collapsed and uncertainty spiraled.
"What we told hedge funds is that we are staring directly into a 2020-like shock," Vårdal said, highlighting how an external disruption—this time tariffs, not a virus—is hitting supply chains, crushing cyclical indicators and fueling dangerous feedback loops.
The Dallas Federal Reserve's latest manufacturing survey plunged to 45.3 in April, dragging the regional average for factory activity well below the 50-line that separates expansion from contraction. The broader ISM Manufacturing Index, due later this week, is still expected to come in at a subdued 48.
Larsen is speculating that a &#8220;big bond trade&#8221;—hinting at a long position in U.S. Treasuries—may be just ahead of us.
"The 48 consensus is amusingly complacent, in my honest opinion," said Steno Research strategist Andreas Steno Larsen in a post on X, suggesting that Wall Street may be underestimating the severity of the slowdown. 
Larsen said the current supply-demand dislocation mirrors the &#8220;lockdown/reopening logic&#8221; of 2020, particularly if Trump's administration gradually dials back tariffs later on.
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45074861/us-consumer-expectations-falls-to-13-year-lows-as-recession-fears-inflation-worries-surge">US Consumer Expectations Falls To 13-Year Lows As Recession Fears, Inflation Worries Surge</a></li>
</ul>
Image: Shutterstock

Analyst Color

Macro Economic Events

Econ #s

Economics

Analyst Ratings

Q1 GDP Recession Bets Spike As Trump Tariffs Fuel 2020-Style Economic Shock

Global Industrial shares are trading higher after the company reported Q1 financial results and beat its EPS and sales estimates.

MSA Safety (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSA#NYSE">MSA</a>) reported quarterly earnings of $1.68 per share which beat the analyst consensus estimate of $1.58 by 6.33 percent. This is a 4.35 percent increase over earnings of $1.61 per share from the same period last year. The company reported quarterly sales of $421.34 million which beat the analyst consensus estimate of $402.63 million by 4.65 percent. This is a 1.94 percent increase over sales of $413.30 million the same period last year.

MSA Safety Q1 Adj. EPS $1.68 Beats $1.58 Estimate, Sales $421.34M Beat $402.63M Estimate

Veralto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLTO#NYSE">VLTO</a>) reported quarterly earnings of $0.95 per share which beat the analyst consensus estimate of $0.87 by 9.2 percent. This is a 13.1 percent increase over earnings of $0.84 per share from the same period last year. The company reported quarterly sales of $1.33 billion which beat the analyst consensus estimate of $1.28 billion by 4.01 percent. This is a 6.90 percent increase over sales of $1.25 billion the same period last year.

Veralto Q1 Adj. EPS $0.95 Beats $0.87 Estimate, Sales $1.33B Beat $1.28B Estimate

Rafael Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RFL#NYSE">RFL</a>) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing stockholders and holders of our public warrants ("Holders") the opportunity to purchase additional shares of Rafael Holdings' Class B common stock, par value $0.01 per share ("Class B Common Stock"), subject to the terms outlined below for an aggregate offering of $25 million. The funds provide the Company additional capital for the potential launch of Trappsol&#xAE;&nbsp;Cyclo&#x2122; in the event of a positive interim result from the 48-week interim analysis of the TransportNPC&#x2122; Phase 3 clinical trial in Niemann-Pick Disease Type&nbsp;C1 ("NPC1").
Holders of record as of May 9, 2025 (the "Record Date") will be eligible to participate in the rights offering. To be considered a Holder of record on the Record Date, prospective Holders must complete open market purchases by May 8, 2025.

Biotech

Offerings

Rafael Holdings Announces Proposed Terms Of $25M Rights Offering To Support Its Commitment To Development And Potential Launch Of Trappsol Cyclo.

Stride shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance.

Unum Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) lowers FY2025 Adj EPS guidance from $9.12-$9.45 to $8.95-$9.28 vs $9.02 analyst estimate..

Unum Gr Lowers FY2025 Adj EPS Guidance from $9.12-$9.45 to $8.95-$9.28 vs $9.02 Est

Vicor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VICR#NASDAQ">VICR</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.20 by 70 percent. This is unchanged from the same period last year. The company reported quarterly sales of $93.97 million which missed the analyst consensus estimate of $96.63 million by 2.76 percent. This is a 12.04 percent increase over sales of $83.87 million the same period last year.

VICR

Vicor Q1 EPS $0.06 Misses $0.20 Estimate, Sales $93.97M Miss $96.63M Estimate

BBIO

BridgeBio Pharma shares are trading higher after the company reported better-than-expected Q1 financial results.

Springview Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) ("Springview Holdings", or the "Company"), a company which designs and constructs residential and commercial buildings in Singapore with an operating history dating back to 2002, today announced that on April 25, 2025, it received a letter from The Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). It resulted from the fact that the closing bid price of the Company's ordinary shares was below $1.00 per share for a period of 30 consecutive business days from March 13, 2025 to April 24, 2025. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The notification has no immediate effect on the listing of the Company's ordinary shares, which will continue to trade uninterrupted on Nasdaq under the ticker "SPHL".
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until October 22, 2025 (the "Compliance Period"), to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per share of the Company's ordinary shares is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed.

SPHL

Springview Holdings Receives Nasdaq Non-Compliance Notice; Granted 180 Days to Regain $1.00 Bid Price

Comments

ARK Genomic Revolution ETF

Actualités

Dernières nouvelles pour ARK Genomic Revolution ETF (BATS:ARKG)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL